Derrell

cTRL Therapeutics Appoints Derrell D. Porter, M.D., as Chief Executive Officer

Retrieved on: 
Wednesday, November 1, 2023
Acumen, Perelman School of Medicine at the University of Pennsylvania, Health, Therapy, Biotechnology, CtrlS, Key, Derrell, Cell, Gilead Sciences, Wharton School of the University of Pennsylvania, Commercial, Amgen, Cancer, Head, Blood, University, AbbVie, McKinsey & Company, Patient, SAN, Pharmaceutical industry, Medical imaging, Neuroscience

SAN FRANCISCO, Nov. 1, 2023 /PRNewswire/ -- cTRL Therapeutics, a biotechnology company harnessing circulating tumor-reactive lymphocytes (cTRLs) in the blood to broaden the power and reach of solid tumor cell therapy to more patients, today announced the appointment of Derrell D. Porter, M.D., as Chief Executive Officer. Dr. Porter has over 20 years of biopharmaceutical leadership experience, bringing deep interdisciplinary expertise in the development and commercialization of innovative therapeutics in oncology and cell and gene therapy.

Key Points: 
  • SAN FRANCISCO, Nov. 1, 2023 /PRNewswire/ -- cTRL Therapeutics, a biotechnology company harnessing circulating tumor-reactive lymphocytes (cTRLs) in the blood to broaden the power and reach of solid tumor cell therapy to more patients, today announced the appointment of Derrell D. Porter, M.D., as Chief Executive Officer.
  • Dr. Porter has over 20 years of biopharmaceutical leadership experience, bringing deep interdisciplinary expertise in the development and commercialization of innovative therapeutics in oncology and cell and gene therapy.
  • "I'm excited to join cTRL at this pivotal moment of discovery for cell therapies targeted to solid tumors, which make up 90% of adult cancers," said Derrell Porter, M.D., Chief Executive Officer of cTRL Therapeutics.
  • "Derrell's experience includes a rare mix of business acumen, clinical development expertise, deep knowledge of the oncology space, and a passion for leading innovation in new treatment modalities that can benefit patients," said Shana Kelley, Ph.D., Founder and Chief Technology Officer of cTRL Therapeutics.

Derrel's Mini Storage, Inc., Select Tenant, Inc.'s Software Technology Platform to Manage Their End-to-End Self-Storage Operations

Retrieved on: 
Tuesday, August 29, 2023
Communication, Software as a service, Collaboration, Darrell, Self, Ecosystem, Derrell, Automation, Central Valley, Video game, Property management, Tenant

Derrel's began their relationship with Tenant in 2020, when they transitioned their storage facilities to Tenant, Inc.'s self-storage website rental platform.

Key Points: 
  • Derrel's began their relationship with Tenant in 2020, when they transitioned their storage facilities to Tenant, Inc.'s self-storage website rental platform.
  • Through the success of that relationship, they chose to continue to the next level by adopting Tenant, Inc.'s property management software, merchant platform, and digital marketing services to manage their operations.
  • "We consider it an accomplishment to have been chosen by Derrel's as a technology partner.
  • Derrel's has fully immersed in the Tenant technology ecosystem, from their website presence and property management operations, to payment processing and accounting.

Cellevolve Announces Global Partnership with QIMR Berghofer Medical Research Institute to Advance Novel Off-the Shelf T-cell Therapy in the First Randomized Cell Therapy Trial for Progressive Multifocal Leukoencephalopathy (PML)

Retrieved on: 
Wednesday, December 1, 2021
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Patient, BK, Demyelinating disease, HLA, PML, CE, Human polyomavirus 2, NORD, Company, Immunodeficiency, Center, VST, Partnership, MD, JC, Match, MBA, QIMR Berghofer Medical Research Institute, IND, Progressive multifocal leukoencephalopathy, George Washington University School of Medicine & Health Sciences, Central nervous system, Doctor of Philosophy, ISCB Senior Scientist Award, BK virus, Therapy, Professor, Infrastructure as code, Washington University School of Medicine, Research, NASDAQ, Derrell, Social media, HIV disease progression rates, QIMR, FDA, Science, Regenerative medicine, Bio, Disease, Immunotherapy, Clinical Neuropharmacology, Pharmaceutical industry, Vaccine

Cellevolve Bio (the Company or Cellevolve), a development and commercialization company focused on cell therapies, today announced a broad-based collaboration with Australia-based QIMR Berghofer Medical Research Institute and its cell therapy manufacturing facility Q-Gen Cell Therapeutics.

Key Points: 
  • Cellevolve Bio (the Company or Cellevolve), a development and commercialization company focused on cell therapies, today announced a broad-based collaboration with Australia-based QIMR Berghofer Medical Research Institute and its cell therapy manufacturing facility Q-Gen Cell Therapeutics.
  • The initial therapeutic focus is on progressive multifocal leukoencephalopathy (PML), a demyelinating disease of the central nervous system caused by JC polyomavirus (JCPyV) occurring in immunocompromised patients.
  • We are honored to partner with leading VST researcher Professor Khanna and his team at QIMR Berghofer to advance a novel, bioengineered, JCV-specific off-the-shelf T-cell therapy to the clinic in this first randomized cell therapy clinical trial.
  • Cellevolve has received initial FDA feedback for its clinical development plan for the JCPyV VST (CE-VST01-JC) and IND submission is planned for the first half of 2022.